# A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.

> **NCT00832052** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 32 (actual)

## Conditions studied

- Healthy
- Elderly

## Interventions

- **DRUG:** PF-04447943
- **DRUG:** PF-04447943
- **DRUG:** PF-04447943
- **DRUG:** PF-04447943
- **DRUG:** PF-04447943

## Key facts

- **NCT ID:** NCT00832052
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2009-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00832052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00832052, "A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00832052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*